59 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
8 May 24
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
7:15am
ligand, which allows the lipid nanoparticle (LNP) to access liver cells using either the asialoglycoprotein receptor (ASGPR) or the low-density
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained … number located in the box above available when you access the website and follow the instructions. Copyright © 2024 BetaNXT, Inc. or its affiliates
8-K
VERV
Verve Therapeutics Inc
2 Apr 24
Other Events
7:13am
tolerated in these trials. Second, the incorporation of GalNAc allows the LNP in VERVE-102 to access liver cells using either the asialoglycoprotein
8-K
EX-99.1
230z uadk
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
8-K
EX-1.1
5s5ypra0qzh9is9
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
424B5
1ptciw65v7z abj
29 Nov 23
Prospectus supplement for primary offering
4:47pm
424B5
1ftrsw5 3h0i
28 Nov 23
Prospectus supplement for primary offering
4:25pm
DEFA14A
2xtqf3briot2dfnj6oc
28 Apr 23
Additional proxy soliciting materials
7:49am